D Valteau-Couanet
Overview
Explore the profile of D Valteau-Couanet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
691
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berlanga P, Pasqualini C, Potschger U, Sanguesa C, Castellani M, Canete A, et al.
Eur J Cancer
. 2020 Dec;
144:1-8.
PMID: 33316634
Background: There is rising concern on the impact of new strategies, such as high-dose chemotherapy (HDC) and immunotherapy, on the pattern of relapse in high-risk neuroblastoma (HR-NBL). Our aim is...
2.
Lobon-Iglesias M, Giraud G, Castel D, Philippe C, Debily M, Briandet C, et al.
J Neurooncol
. 2017 Dec;
137(1):111-118.
PMID: 29198053
Children with diffuse intrinsic pontine glioma (DIPG) need new and more efficient treatments. They can be developed at relapse or at diagnosis, but therefore they must be combined with radiotherapy....
3.
Fresneau B, Fayech C, Butel T, Haddy N, Valteau-Couanet D, Ou P
Rev Med Interne
. 2016 Sep;
38(2):125-132.
PMID: 27639916
Anthracycline-induced cardiotoxicity (ACT) is a severe complication in children and young adults that may lead to congestive heart failure. Some risk factors have been identified: high anthracycline cumulative dose, high...
4.
Dourthe M, Ternes N, Gajda D, Paci A, Dufour C, Benhamou E, et al.
Bone Marrow Transplant
. 2016 Apr;
51(9):1265-7.
PMID: 27111042
No abstract available.
5.
Proust-Houdemont S, Pasqualini C, Blanchard P, Dufour C, Benhamou E, Goma G, et al.
Bone Marrow Transplant
. 2016 Apr;
51(8):1076-81.
PMID: 27042850
High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL...
6.
Vassal G, Landman-Parker J, Baruchel A, Bergeron C, Rubie H, Coze C, et al.
Arch Pediatr
. 2015 Nov;
22(12):1217-22.
PMID: 26604021
Introduction: According to the European Society of Pediatric Oncology (SIOPE) standard of care guidelines, high-quality care of children and adolescents with cancer needs to be delivered by well-trained multidisciplinary teams...
7.
Pasqualini C, Dufour C, Goma G, Raquin M, Lapierre V, Valteau-Couanet D
Bone Marrow Transplant
. 2015 Nov;
51(2):227-31.
PMID: 26524264
High-risk neuroblastoma is characterised by poor long-term survival, especially for very high-risk (VHR) patients (poor response of metastases after induction therapy). We report the results of an intensified high-dose chemotherapy...
8.
Longaud-Vales A, Chevignard M, Dufour C, Grill J, Puget S, Sainte-Rose C, et al.
Neuropsychol Rehabil
. 2015 Aug;
26(4):558-83.
PMID: 26272265
There is a lack of studies assessing executive functions (EF) using ecologically valid tests in children with frontal lobe lesions. This study aimed to (1) evaluate EF in children, adolescents...
9.
Loschi S, Dufour C, Oberlin O, Goma G, Valteau-Couanet D, Gaspar N
Bone Marrow Transplant
. 2015 Jun;
50(8):1083-8.
PMID: 26030048
The prognosis of primary disseminated multifocal metastatic Ewing's sarcoma (PDMES) is poor even if a slight improvement has been achieved with high-dose alkylating agent-containing chemotherapy. To enhance treatment efficacy, we...
10.
Kohler J, Rubie H, Castel V, Beiske K, Holmes K, Gambini C, et al.
Eur J Cancer
. 2013 Aug;
49(17):3671-9.
PMID: 23907002
Background: In children older than 1 year with localised unresectable neuroblastoma (NB), treatment strategies are heterogeneous according to the national groups. The objective of this phase III non-randomised study was...